- Release Date: 15/05/25 08:24
- Summary: PAR Receives US Ethics Approval for Phase 3
- Price Sensitive: Yes
- Download Document 153.91KB
- Forums
- ASX - By Stock
- PAR
- Ann: PAR Receives US Ethics Approval for Phase 3
PAR
paradigm biopharmaceuticals limited..
Add to My Watchlist
0.00%
!
31.5¢

Ann: PAR Receives US Ethics Approval for Phase 3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
31.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $125.1M |
Open | High | Low | Value | Volume |
31.0¢ | 32.0¢ | 30.8¢ | $160.8K | 514.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 315 | 31.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.5¢ | 2804 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 315 | 0.310 |
5 | 113300 | 0.305 |
17 | 244139 | 0.300 |
7 | 108371 | 0.295 |
11 | 237602 | 0.290 |
Price($) | Vol. | No. |
---|---|---|
0.315 | 2804 | 2 |
0.320 | 4000 | 1 |
0.335 | 15000 | 1 |
0.340 | 61516 | 3 |
0.350 | 7689 | 2 |
Last trade - 16.10pm 11/08/2025 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
WIN
WIN METALS LTD
Steve Norregard, CEO & MD
Steve Norregard
CEO & MD
SPONSORED BY The Market Online